

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

STRATEGIC COLLABORATION AGREEMENTS IN THE FIELD OF ARTIFICIAL INTELLIGENCE (AI) IN INNOVATIVE DRUG RESEARCH AND DEVELOPMENT

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has entered into strategic collaboration agreements (the “**Agreements**”) with Insilico Medicine Ltd. (“**Insilico Medicine**”) and Shenzhen XtalPi Technology Co., Ltd. (“**XtalPi Technology**”) in the field of artificial intelligence (AI) in innovative drug research and development respectively.

Pursuant to the Agreements, the Group’s expertise in drug research and development and the leading AI technology platforms of Insilico Medicine and XtalPi Technology in innovative drug research and development will be leveraged, using AI in drug design to improve the efficiency and success rate of new drug screening, to promote the Group’s research and development of innovative drugs with focus on strategic product types with high clinical needs.

About Insilico Medicine

Insilico Medicine, a biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of drug candidates with specific molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs to fulfill the unmet medical needs in cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases.

About XtalPi Technology

XtalPi Technology is an innovative technology company powered by AI and robotics. Founded in 2014 at MIT in the U.S., the company is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With cutting-edge technology and capability in quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi Technology offers a range of innovative technology solutions, services, and products for the biopharmaceutical, chemical, new energy and new materials industries worldwide.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 21 August 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.